Phase 1/2 × Sarcoma × Clear all
NCT03093116 2026-04-03

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 5 FDA
NCT07410676 2026-02-18

EBNK-ST-001

Essen Biotech

Phase 1/2 Recruiting
83 enrolled